2-cyclopropyl-6-iodo-3-methylimidazo[1,2-a]pyridine | 1447910-77-1

分子结构分类

有机化合物 - 有机杂环化合物 - 咪唑并吡啶类

中文名称

——

中文别名

——

英文名称

2-cyclopropyl-6-iodo-3-methylimidazo[1,2-a]pyridine

英文别名

——

2-cyclopropyl-6-iodo-3-methylimidazo[1,2-a]pyridine化学式

CAS

1447910-77-1

化学式

C₁₁H₁₁IN₂

mdl

——

分子量

298.126

InChiKey

HBWPQKSZMWTJEZ-UHFFFAOYSA-N

BEILSTEIN

——

EINECS

——

物化性质

密度：

1.90±0.1 g/cm3(Predicted)

计算性质

辛醇/水分配系数(LogP)：

3.4
重原子数：

14
可旋转键数：

1
环数：

3.0
sp3杂化的碳原子比例：

0.36
拓扑面积：

17.3
氢给体数：

0
氢受体数：

1

上下游信息

下游产品

中文名称	英文名称	CAS号	化学式	分子量
——	2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-amine	869184-20-3	C₁₁H₁₃N₃	187.244
——	(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)boronic acid	1447910-89-5	C₁₁H₁₃BN₂O₂	216.047
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-hydroxypyridin-2(1H)-one	1447911-19-4	C₁₆H₁₅N₃O₂	281.314
——	4-bromo-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-20-3	C₁₆H₁₄BrN₃O	344.211
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(hydroxymethyl)pyridin-2(1H)-one	1447913-37-2	C₁₇H₁₇N₃O₂	295.341
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(pyridin-4-ylmethoxy)pyridin-2(1H)-one	1447912-77-7	C₂₂H₂₀N₄O₂	372.426
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(pyrimidin-5-ylmethoxy)pyridin-2(1H)-one	1447912-87-9	C₂₁H₁₉N₅O₂	373.414
——	4-((E)-2-(4-chlorophenyl)ethenyl)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-64-5	C₂₄H₂₀ClN₃O	401.895
——	4-(benzyloxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447910-95-3	C₂₃H₂₁N₃O₂	371.439
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(pyridin-3-ylmethoxy)pyridin-2(1H)-one	1447912-73-3	C₂₂H₂₀N₄O₂	372.426
——	4-((4-chlorobenzyl)amino)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-63-4	C₂₃H₂₁ClN₄O	404.899
——	4-((4-chlorobenzyl)oxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447910-81-7	C₂₃H₂₀ClN₃O₂	405.884
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-((4-fluorophenoxy)methyl)pyridin-2(1H)-one	1447913-35-0	C₂₃H₂₀FN₃O₂	389.429
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-((4-fluorobenzyl)oxy)pyridin-2(1H)-one	1447910-75-9	C₂₃H₂₀FN₃O₂	389.429
——	methyl 1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-2-oxo-1,2-dihydropyridine-4-carboxylate	1447913-36-1	C₁₈H₁₇N₃O₃	323.351
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-{[4-(propan-2-yl)benzyl]oxy}pyridin-2(1H)-one	1447913-67-8	C₂₆H₂₇N₃O₂	413.519
——	4-((4-bromobenzyl)oxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-68-9	C₂₃H₂₀BrN₃O₂	450.335
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(thiophen-3-ylmethoxy)pyridin-2(1H)-one	1447912-92-6	C₂₁H₁₉N₃O₂S	377.467
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(pyridin-2-ylmethoxy)pyridin-2(1H)-one	——	C₂₂H₂₀N₄O₂	372.426
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-(thiophen-2-ylmethoxy)pyridin-2(1H)-one	1447912-91-5	C₂₁H₁₉N₃O₂S	377.467
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-((3-fluorobenzyl)oxy)pyridin-2(1H)-one	1447912-89-1	C₂₃H₂₀FN₃O₂	389.429
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-((4-(trifluoromethyl)benzyl)oxy)pyridin-2(1H)-one	1447910-84-0	C₂₄H₂₀F₃N₃O₂	439.437
——	4-((4-tert-butylbenzyl)oxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-66-7	C₂₇H₂₉N₃O₂	427.546
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-[4-(trifluoromethoxy)phenoxy]pyridin-2(1H)-one	——	C₂₃H₁₈F₃N₃O₃	441.409
——	4-((4-chlorobenzyl)oxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyrimidin-2(1H)-one	1447911-95-6	C₂₂H₁₉ClN₄O₂	406.871
——	4-((4-chlorothiophen-2-yl)methoxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2 (1H)-one	1447913-33-8	C₂₁H₁₈ClN₃O₂S	411.912
——	4-((5-chloro-2-thienyl)methoxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447912-99-3	C₂₁H₁₈ClN₃O₂S	411.912
——	4-((5-chlorothiophen-3-yl)methoxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-28-1	C₂₁H₁₈ClN₃O₂S	411.912
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-((5-fluorothiophen-2-yl)methoxy)pyridin-2(1H)-one	1447913-19-0	C₂₁H₁₈FN₃O₂S	395.457
——	1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-((2,4-difluorobenzyl)oxy)pyridin-2(1H)-one	1447911-18-3	C₂₃H₁₉F₂N₃O₂	407.42
——	4-((5-chloropyridin-2-yl)methoxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447911-38-7	C₂₂H₁₉ClN₄O₂	406.871
——	4-((5-bromo-3-thienyl)methoxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-48-5	C₂₁H₁₈BrN₃O₂S	456.363
——	4-((4-chloro-3-fluorobenzyl)oxy)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-14-5	C₂₃H₁₉ClFN₃O₂	423.874
——	4-(((5-chloro-2-thienyl)methyl)amino)-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one	1447913-52-1	C₂₁H₁₉ClN₄OS	410.927

反应信息

作为反应物：

描述：

2-cyclopropyl-6-iodo-3-methylimidazo[1,2-a]pyridine 在 copper(l) iodide 、 palladium 10% on activated carbon 、氢气、 potassium carbonate 、 N,N'-二甲基乙二胺作用下，以甲醇、二甲基亚砜、 N,N-二甲基甲酰胺为溶剂，反应 18.0h，生成 1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)-4-{[4-(propan-2-yl)benzyl]oxy}pyridin-2(1H)-one

参考文献：

名称：

缺乏脂肪胺的黑色素浓缩激素受体1拮抗剂：新型1-（咪唑并[1,2 - a ]吡啶-6-基）吡啶-2（1 H）-一衍生物的合成与结构-活性关系

摘要：

为了发现具有改善的安全性的黑色素浓缩激素受体1（MCHR1）拮抗剂，我们假设，如果化合物支架的双环基序与Asp123和/或Tyr272相互作用，则迄今为止报道的大多数拮抗剂中使用的脂肪胺都可以被去除。 MCHR1。我们从化合物设计中排除了p K a <8的临界值的脂族胺，并在面向CNS的化学空间（受四个描述符（TPSA，ClogP，MW和HBD计数）限制）中探索了不含脂族胺的MCHR1拮抗剂。。对具有高固有结合亲和力的MCHR1新型双环基序的筛选确定了咪唑并[1,2- a ]吡啶环（以化合物6a和6b表示），然后对中央脂肪族酰胺键进行环化，导致发现了一种有效的，口服可生物利用的MCHR1拮抗剂4-[（（4-氯苄基）氧基] -1-（2-环丙基-3-甲基咪唑并[1,2- a] ] pyridin-6-yl）pyridin-2（1 H）-one 10a。它在饮食诱导的肥胖大鼠中表现出低的hER

DOI：

10.1021/acs.jmedchem.5b01704
作为产物：

描述：

2-氨基-5-碘吡啶在吡啶、 sodium hydride 、三氟乙酸酐作用下，以四氢呋喃、 N,N-二甲基甲酰胺、 mineral oil 为溶剂，反应 3.0h，生成 2-cyclopropyl-6-iodo-3-methylimidazo[1,2-a]pyridine

参考文献：

名称：

[EN] BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS
[FR] DÉRIVÉS DE BENZIMIDAZOLE COMME ANTAGONISTES DU RÉCEPTEUR MCH

摘要：

本发明提供了一种具有黑色素浓集激素受体拮抗作用并且用作预防或治疗肥胖等疾病的芳香环化合物。本发明涉及一种由式(I)表示的化合物，其中每个符号如规范中定义的，或其盐。

公开号：

WO2013105676A1

点击查看最新优质反应信息

文献信息

BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS

申请人：Takeda Pharmaceutical Company Limited

公开号：US20150018363A1

公开（公告）日：2015-01-15

The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

本发明提供了一种具有黑色素浓缩激素受体拮抗作用的芳香环化合物，可用作预防或治疗肥胖等药物。本发明涉及一种由式中定义的每个符号或其盐所表示的化合物。
AROMATIC RING COMPOUND

申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

公开号：US20150087672A1

公开（公告）日：2015-03-26

The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

本发明提供了一种具有黑素浓缩激素受体拮抗作用的芳香环化合物，可用作预防或治疗肥胖等药物。本发明涉及一种由式中每个符号如规范中定义或其盐所表示的化合物。
Benzimidazole derivatives as MCH receptor antagonists

申请人：Takeda Pharmaceutical Company Limited

公开号：US09365540B2

公开（公告）日：2016-06-14

The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

本发明提供了一种具有黑色素浓缩激素受体拮抗作用的芳香环化合物，可用作预防或治疗肥胖等疾病的药剂。本发明涉及一种由式中定义的每个符号或其盐表示的化合物。
Aromatic ring compound

申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

公开号：US09440987B2

公开（公告）日：2016-09-13

The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

本发明提供了一种芳香环化合物，具有黑色素浓缩激素受体拮抗作用，可用作预防或治疗肥胖等药物。本发明涉及一种化合物，其表示为式中的符号在说明书中定义，或其盐。
EP2848621

申请人：——

公开号：——

公开（公告）日：——